Two newer FDA-approved treatments for hyperlipidemia are gaining popularity due to their effectiveness and dosing. A statin alternative, Nexletol (bempedoic acid) received FDA approval in 2020, but a new study published in NEJM provides information that the drug is effective in reducing the risk of heart disease.
Recommended for NPs: Cardiac Essentials Package
Cardiovascular disease carries high morbidity and mortality worldwide. Tight control of hyperlipidemia is essential in preventing CV disease. This is especially good news for those patients who are statin intolerant, as bempedoic acid is effective in lowering LDL.
The CLEAR Outcomes Trial analyzed data in a double-blinded, randomized, placebo-controlled trial from over 13,900 participants who were statin-intolerant. Their findings demonstrated a 21% reduction in LDL as well as decreased rates of death due to cardiovascular events, nonfatal MIs, nonfatal strokes and angioplasty by 13%.
Leqvio (inclisiran) is a subcutaneous injection administered by a clinician every 6 months and is typically prescribed for those on maximum doses of statins in adults with heterozygous familial hypercholesteremia (HeFH) or evidence of clinical atherosclerotic cardiovascular disease (ASCVD) although the role on the effect on morbidity and mortality has not yet been established.
